- Home
- ANL vs MNOV Comparison
ANL vs MNOV Comparison
Compare ANL & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- MNOV
- Stock Information
- Founded
- ANL 2004
- MNOV 2000
- Country
- ANL Cayman Islands
- MNOV United States
- Employees
- ANL N/A
- MNOV N/A
- Industry
- ANL
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- MNOV Health Care
- Exchange
- ANL Nasdaq
- MNOV Nasdaq
- Market Cap
- ANL 61.8M
- MNOV 65.7M
- IPO Year
- ANL 2023
- MNOV 2005
- Fundamental
- Price
- ANL $1.66
- MNOV $1.23
- Analyst Decision
- ANL Hold
- MNOV Strong Buy
- Analyst Count
- ANL 1
- MNOV 2
- Target Price
- ANL N/A
- MNOV $7.00
- AVG Volume (30 Days)
- ANL 7.7K
- MNOV 25.7K
- Earning Date
- ANL 11-04-2025
- MNOV 11-12-2025
- Dividend Yield
- ANL N/A
- MNOV N/A
- EPS Growth
- ANL N/A
- MNOV N/A
- EPS
- ANL N/A
- MNOV N/A
- Revenue
- ANL N/A
- MNOV $134,599.00
- Revenue This Year
- ANL N/A
- MNOV N/A
- Revenue Next Year
- ANL N/A
- MNOV N/A
- P/E Ratio
- ANL N/A
- MNOV N/A
- Revenue Growth
- ANL N/A
- MNOV N/A
- 52 Week Low
- ANL $1.10
- MNOV $1.13
- 52 Week High
- ANL $3.89
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- ANL 46.43
- MNOV 44.15
- Support Level
- ANL $1.60
- MNOV $1.23
- Resistance Level
- ANL $1.73
- MNOV $1.26
- Average True Range (ATR)
- ANL 0.08
- MNOV 0.03
- MACD
- ANL -0.01
- MNOV -0.00
- Stochastic Oscillator
- ANL 43.08
- MNOV 25.00
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.